Last reviewed · How we verify

BioNTech SE — Portfolio Competitive Intelligence Brief

BioNTech SE pipeline: 0 marketed, 0 filed, 6 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 6 Phase 3 8 Phase 2 31 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Investigational Influenza Vaccine Investigational Influenza Vaccine phase 3 Infectious Disease
BNT162b2.B.1.351 BNT162b2.B.1.351 phase 3 mRNA vaccine SARS-CoV-2 spike protein (B.1.351 variant) Immunology / Infectious Disease
BNT323/DB-1303 BNT323/DB-1303 phase 3 Bispecific antibody Oncology
BNT324 BNT324 phase 3 mRNA vaccine RSV (Respiratory Syncytial Virus) antigens Immunology / Infectious Disease
Pumitamig Pumitamig phase 3 Other
Nab-paclitaxel/Paclitaxel Nab-paclitaxel/Paclitaxel phase 3 Microtubule stabilizer / Taxane β-tubulin / Microtubules Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 2 shared drug classes
  2. Allakos Inc. · 1 shared drug class
  3. AstraZeneca · 1 shared drug class
  4. Amgen · 1 shared drug class
  5. Arcturus Therapeutics, Inc. · 1 shared drug class
  6. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  7. Allergan · 1 shared drug class
  8. Air Force Military Medical University, China · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for BioNTech SE:

Cite this brief

Drug Landscape (2026). BioNTech SE — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biontech-se. Accessed 2026-05-13.

Related